Business Wire

HISENSE

1.6.2021 12:00:08 CEST | Business Wire | Press release

Share
Building Sustainable Future: Hisense and Employees

Living under the new-normal, ESG has become one of the world's most trending topics. A positive impact on society and providing sustainable development opportunities for employees have gradually become the new criteria for companies to represent their growth. By putting talent first, Hisense strives to build a global team that includes people from different cultures and unique experiences, and to provide an equal and healthy working environment to drive its success. Together with over 90,000 employees around the world, Hisense is creating a sustainable future and exerting positive social influence constantly.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005474/en/

Focusing on local talent cultivation and cultural inclusion

Hisense supports local communities to relieve their unemployment pressure and to reduce the indirectly related crime rate. Through its investment in industrial parks worldwide, Hisense creates more than 3,000 job positions in South Africa and over 2,000 in Mexico with an expectation to expand to over 7,000 in the future, which successfully helps the local region expand its economy and boost sustainable development.

Hisense provides equal employment opportunities regardless of race and gender with professional and systematic training when recruiting local employees. For example, Nicalette, a single mother, who joined Hisense South Africa in 2002, was promoted to After-sales Manager through her excellent work performance and rapidly growing ability. Hisense’s talent employment and cultivation system has increased her passion for work and also made her life improved, according to Nicalette.

Caring for employees' career development

To empower employees, Hisense has created the necessary conditions and space for them to maximize their potential and value. Hisense implements a flexible promotion mechanism, allowing employees to choose between career paths of “management” and “R&D” for further development, which ensures a smooth promotion channel for everyone.

Hisense College, the corporate university, aims to help employees achieve better career development. A comprehensive training structure and multiple internal training platforms (including offline lecture, website, APP, etc.) are in place to help employees learn and improve anytime, anywhere.

"What makes working here different from other companies is that Hisense always motivates its employees to accomplish career goals and gives them great supports, allowing them to grow with the company." said Robin Silberbauer, who joined Hisense South Africa in 2015.

Caring for employees' health and wellbeing

During the pandemic, Hisense spares no efforts to assure employees' and their families' health through distributing epidemic prevention materials and supporting working at home.

Hisense also joins hands with professional EAP (“Employee Assistance Program”) organizations to provide mental health care for employees and their families, so that each employee can easily obtain professional psychological counselling services, which efficiently help them improve mental health and take up challenges of work and life.

Hisense will focus on talent development in the long term and actively create an inclusive workplace environment to advance the sustainable development of local communities with its global workforce.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye